Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares Purchased by GSA Capital Partners LLP

Key Points

• GSA Capital Partners LLP significantly increased its holdings in Ironwood Pharmaceuticals by 3,683.6%, acquiring a total of 524,676 shares worth approximately $771,000.
• Ironwood Pharmaceuticals reported a loss of $0.14 per share for the recent quarter, missing analyst expectations, and generated $41.14 million in revenue, falling short of the anticipated $67.02 million.
• Several analysts downgraded the company's stock ratings, with target prices reduced to as low as $1.00, resulting in a consensus rating of "Hold" and an average price target of $4.78.

GSA Capital Partners LLP boosted its stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 3,683.6% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 524,676 shares of the biotechnology company's stock after buying an additional 510,809 shares during the period. GSA Capital Partners LLP owned approximately 0.32% of Ironwood Pharmaceuticals worth $771,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Raymond James Financial Inc. bought a new stake in Ironwood Pharmaceuticals in the 4th quarter valued at about $68,000. KLP Kapitalforvaltning AS bought a new stake in Ironwood Pharmaceuticals in the 4th quarter valued at about $107,000. Norges Bank bought a new stake in shares of Ironwood Pharmaceuticals during the 4th quarter worth approximately $1,118,000. Geode Capital Management LLC lifted its holdings in shares of Ironwood Pharmaceuticals by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 3,306,570 shares of the biotechnology company's stock worth $14,652,000 after acquiring an additional 13,028 shares during the period. Finally, Envestnet Asset Management Inc. bought a new stake in shares of Ironwood Pharmaceuticals during the 4th quarter worth approximately $50,000.

Ironwood Pharmaceuticals Stock Up 1.0%

Ironwood Pharmaceuticals stock traded up $0.01 during mid-day trading on Friday, reaching $0.77. 1,107,061 shares of the company's stock were exchanged, compared to its average volume of 1,195,990. The firm has a market capitalization of $124.83 million, a PE ratio of -3.86 and a beta of 0.33. Ironwood Pharmaceuticals, Inc. has a one year low of $0.53 and a one year high of $6.57. The business's fifty day simple moving average is $0.72 and its 200 day simple moving average is $1.27.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.09). The business had revenue of $41.14 million during the quarter, compared to the consensus estimate of $67.02 million. Ironwood Pharmaceuticals had a negative net margin of 9.89% and a negative return on equity of 1.87%. On average, sell-side analysts forecast that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current year.

Analysts Set New Price Targets

IRWD has been the subject of a number of recent research reports. Wall Street Zen raised Ironwood Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. Jefferies Financial Group reiterated a "hold" rating and set a $0.70 price objective (down from $8.00) on shares of Ironwood Pharmaceuticals in a research report on Tuesday, April 15th. Citizens Jmp cut shares of Ironwood Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research report on Monday, April 14th. Leerink Partners decreased their price objective on shares of Ironwood Pharmaceuticals from $3.00 to $1.00 and set a "market perform" rating for the company in a research report on Monday, April 14th. Finally, Wells Fargo & Company reiterated an "equal weight" rating and set a $1.00 price objective (down from $7.00) on shares of Ironwood Pharmaceuticals in a research report on Tuesday, April 15th. Seven investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of "Hold" and an average price target of $4.78.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.